Bildquelle:- >> | Inhaltsquelle:- >>
The University of Texas MD Anderson Cancer Institute and the biotech firm Xilis have entered into a strategic partnership to advance science and hasten the development of novel cancer therapies.
The partnership will enhance the development of cancer therapies by combining MD Anderson’s expertise and Xilis’ MOS platform. The preclinical research deal will combine the MicroOrganoSphere (MOS) platform of Xilis with the expertise of MD Anderson for advancing new therapy development and cancer research.
The MOS platform enables translational research on patient-derived microtumors. Additionally, MD Anderson and Xilis aim to explore how the MOS platform facilitates the development of new patient-derived models for studying rare cancers and treatment-resistant disorders. This platform allows a patient tumor response to be quickly evaluated against numerous cancer drugs within two weeks of receiving harvested tumor samples.
Dr. Xiling Shen—CEO and Co-Founder of Xilis—emphasized that the MOS platform can offer new capabilities and improve the efficiency of developing innovative drugs and cell therapies over current xenograft and organoid models, which would remarkably pace up the development and approval of drugs.
Über Ingenious e-Brain:-
Ingenious e-Brain bietet branchenführenden und innovativen Unternehmen weltweit hochwertige, maßgeschneiderte und kosteneffiziente Lösungen in den Bereichen Technologieforschung, Unternehmensforschung und Forschung zu geistigem Eigentum. Innovation, Wissen und Transparenz bilden die Grundlage unserer Unternehmensmission und -vision. Neben Kostenvorteilen liefern wir höchste Qualität der Ergebnisse und gewährleisten dabei absolute Vertraulichkeit und Sicherheit. Wir sind ein ISO-zertifiziertes Unternehmen mit Niederlassungen in Indien und den USA.
Ingenious e-Brain has a strong team of analysts and subject matter experts with domain proficiency that is devoted to helping clients grow. Our highly qualified professionals offer tailored, value-added, and cost-effective services to our clients. We believe in building long-term relationships with our clients which include national and international corporations, Fortune 500 companies, the world’s leading research institutes and universities as well as independent inventors.
Kontaktieren Sie uns:-
Büro Indien
207-208 Welldone TechPark, Sohna Road
Sector 48, Gurugram, Haryana 122018, Indien
+91 124 429 4218
Verwandte Beiträge
Noxopharm in-licenses novel RNA tech for drug discovery, vaccines
